A Phase 3 interventional study of Infliximab and Placebo in Ankylosing Spondylitis and Axial Spondyloarthritis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 48 Years. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing infliximab in Spondylitis, Ankylosing — 1 open to participants now, 1 under way, none of them phase 3. Infliximab · Spondylitis, Ankylosing.
Among the 20 studies testing infliximab in Spondylitis, Ankylosing, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 11th registered.
534 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →1 of the 20 studies testing infliximab in Spondylitis, Ankylosing is open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 48 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 6 · Phase 4 9
First in 2002; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 87 across 304 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 85 across the 20 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
14 studies in Spondylitis, Ankylosing by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 14 studies in Spondylitis, Ankylosing by Merck & Co., Inc, this one is the only one that started in 2009, is one of 3 in phase 3, and was the 9th registered.
Merck & Co., Inc’s Spondylitis, Ankylosing studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing infliximab in Spondylitis, Ankylosing, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 14 in Spondylitis, Ankylosing:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial spondyloarthritis and disease duration of ≤3 years, who achieve the Assessment in Ankylosing Spondylitis (ASAS) partial remission criteria.
In the 28-week treatment phase, participants were randomized to receive either infliximab plus naproxen or placebo plus naproxen.
After 28-weeks of treatment, participants that achieved partial remission in the treatment phase were randomized to continued treatment with naproxen or to receive no treatment and were followed for an additional 24 weeks (follow-up phase).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must:
Exclusion Criteria:
Participant will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
Drug: Infliximab · Drug: Naproxen
Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
Drug: Placebo · Drug: Naproxen
For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
Drug: Naproxen
For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
Also known as: Remicade, SCH 215596
Also known as: Naprosyn
Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28
ASAS domains were measured on a visual analog scale (VAS) of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
Time frame: Week 28
Number of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Follow-Up Phase
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
Time frame: Week 52
Percentage of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Treatment Phase
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
Time frame: Week 52
Change From Baseline of Berlin Magnetic Resonance Imaging (MRI) Spine Overall Score at Week 28
MRI scans (T1 for chronic changes and short tau inversion recovery \[STIR\] for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
Time frame: Baseline, Week 28
Change From Baseline in the Sacroiliac Overall Score at Week 28
Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
Time frame: Baseline, Week 28
Change From Baseline of Berlin MRI Spine Overall Score at Week 52
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
Time frame: Baseline, Week 52
Change From Baseline in the Sacroiliac Overall Score at Week 52
Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
Time frame: Baseline, Week 28
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 28
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.
Time frame: Week 28
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 28
Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions at the sacroiliac joints was defined as a Score = 0.
Time frame: Week 28
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 28
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.
Time frame: Week 28
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 52
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.
Time frame: Week 52
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 52
EaEach sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.
Time frame: Week 52
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 52
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active spinal inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.
Time frame: Week 52
Median Duration of Maintaining ASAS Partial Remission in the Follow-Up Phase
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
Time frame: Week 52
Number of Participants Who Achieved ASAS Partial Remission That Experienced Disease Flare With Naproxen Maintenance Treatment in the Follow-Up Phase
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) employs a VAS of 0mm (best) to 100mm (worst). Disease flare was defined as reaching a BASDAI of ≥30 mm during two consecutive visits after Week 28 until Week 52. ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria was defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
Time frame: Week 52
Percentage of Participants That Achieved ASAS-40 Response at Week 28 in the Treatment Phase
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS-40 response was defined as ASAS achieving ≥40% improvement in 3 of the 4 domains (patient global assessment, total back pain, function, and inflammation), with an absolute improvement of ≥20 mm and no deterioration in the remaining domain.
Time frame: Week 28
Percentage of Participants That Achieved ASAS-20 Response at Week 28 in the Treatment Phase
ASAS-20 response was defined as ≥20% improvement in response according to following criteria: • An improvement of ≥20% from baseline and an absolute improvement from baseline of ≥10 mm in at least 3 of the following 4 domains (patient global assessment, pain, function,and inflammation) • Absence of deterioration from baseline (≥20% and an absolute change of ≥10 mm) in the potential remaining domain.
Time frame: Week 28
| Milestone | Infliximab + Naproxen | Placebo + Naproxen | Naproxen | No Treatment |
|---|---|---|---|---|
| Started | 106 | 52 | 0 | 0 |
| Completed | 96 | 45 | 0 | 0 |
| Not completed | 10 | 7 | 0 | 0 |
| Withdrew: Adverse event | 5 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 0 | 0 |
| Withdrew: Noncompliance with protocol | 1 | 0 | 0 | 0 |
| Withdrew: Did not meet protocol eligibility | 1 | 2 | 0 | 0 |
| Milestone | Infliximab + Naproxen | Placebo + Naproxen | Naproxen | No Treatment |
|---|---|---|---|---|
| Started | 0 | 0 | 41 | 41 |
| Completed | 0 | 0 | 32 | 32 |
| Not completed | 0 | 0 | 9 | 9 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 | 3 |
| Withdrew: Noncompliance with protocol | 0 | 0 | 0 | 1 |
| Withdrew: Relapse/recurrence | 0 | 0 | 2 | 4 |
| Withdrew: Did not meet protocol eligibility | 0 | 0 | 0 | 1 |
ASAS domains were measured on a visual analog scale (VAS) of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
| Participants | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Achieved Partial Remission | 65 | 18 |
| Did Not Achieve Partial Remission | 40 | 33 |
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
| Participants | Naproxen | No Treatment |
|---|---|---|
| Achieved Partial Remission | 19 | 16 |
| Did Not Achieve Partial Remission | 21 | 24 |
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
| Percentage of Participants | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Percentage of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Treatment Phase | 40 | 55 |
MRI scans (T1 for chronic changes and short tau inversion recovery \[STIR\] for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
| Units on a Scale | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Change From Baseline of Berlin Magnetic Resonance Imaging (MRI) Spine Overall Score at Week 28 | -0.5 (-3.5 to 0.0) | 0.0 (-4.7 to 0.0) |
Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
| Units on a Scale | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Change From Baseline in the Sacroiliac Overall Score at Week 28 | -2.0 (-7.0 to -0.5) | -3.0 (-6.5 to -1.0) |
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
| Units on a Scale | Naproxen | No Treatment |
|---|---|---|
| Change From Baseline of Berlin MRI Spine Overall Score at Week 52 | 0.0 (0.0 to 1.0) | 0.0 (0.0 to 2.3) |
Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.
| Units on a Scale | Naproxen | No Treatment |
|---|---|---|
| Change From Baseline in the Sacroiliac Overall Score at Week 52 | 1.1 (0.0 to 4.0) | 1.0 (0.0 to 3.3) |
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.
| Participants | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 28 | 63 | 23 |
Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions at the sacroiliac joints was defined as a Score = 0.
| Participants | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 28 | 29 | 3 |
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.
| Participants | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 28 | 19 | 0 |
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.
| Participants | Naproxen | No Treatment |
|---|---|---|
| Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 52 | 20 | 16 |
EaEach sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.
| Participants | Naproxen | No Treatment |
|---|---|---|
| Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 52 | 3 | 4 |
MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active spinal inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.
| Participants | Naproxen | No Treatment |
|---|---|---|
| Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 52 | 1 | 1 |
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
| Weeks | Naproxen | No Treatment |
|---|---|---|
| Median Duration of Maintaining ASAS Partial Remission in the Follow-Up Phase | 23.00 (3.43 to 26.71) | 12.57 (4.71 to 25.14) |
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) employs a VAS of 0mm (best) to 100mm (worst). Disease flare was defined as reaching a BASDAI of ≥30 mm during two consecutive visits after Week 28 until Week 52. ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria was defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).
| Participants | Naproxen | No Treatment |
|---|---|---|
| Number of Participants Who Achieved ASAS Partial Remission That Experienced Disease Flare With Naproxen Maintenance Treatment in the Follow-Up Phase | 1 | 3 |
ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS-40 response was defined as ASAS achieving ≥40% improvement in 3 of the 4 domains (patient global assessment, total back pain, function, and inflammation), with an absolute improvement of ≥20 mm and no deterioration in the remaining domain.
| Percentage of Participants | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Percentage of Participants That Achieved ASAS-40 Response at Week 28 in the Treatment Phase | 79 | 29 |
ASAS-20 response was defined as ≥20% improvement in response according to following criteria: • An improvement of ≥20% from baseline and an absolute improvement from baseline of ≥10 mm in at least 3 of the following 4 domains (patient global assessment, pain, function,and inflammation) • Absence of deterioration from baseline (≥20% and an absolute change of ≥10 mm) in the potential remaining domain.
| Percentage of Participants | Infliximab + Naproxen | Placebo + Naproxen |
|---|---|---|
| Percentage of Participants That Achieved ASAS-20 Response at Week 28 in the Treatment Phase | 85 | 37 |
Collected over Up to Week 52.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infliximab + Naproxen | — | 6/105 (5.7%) | 24/105 (22.9%) |
| Placebo + Naproxen | — | 3/52 (5.8%) | 8/52 (15.4%) |
| Naproxen | — | 0/41 (0%) | 6/41 (14.6%) |
| No Treatment | — | 3/41 (7.3%) | 11/41 (26.8%) |
| Event | Infliximab + Naproxen | Placebo + Naproxen | Naproxen | No Treatment |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/105 | 1/52 | 0/41 | 1/41 |
| Carcinoma In SituNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/105 | 0/52 | 0/41 | 1/41 |
| Ovarian Cyst RupturedReproductive system and breast disorders | 0/105 | 1/52 | 0/41 | 1/41 |
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 0/105 | 1/52 | 0/41 | 1/41 |
| Ankylosing SpondylitisMusculoskeletal and connective tissue disorders | 0/105 | 1/52 | 0/41 | 0/41 |
| Chest DiscomfortGeneral disorders | 1/105 | 0/52 | 0/41 | 0/41 |
| PneumoniaInfections and infestations | 1/105 | 0/52 | 0/41 | 0/41 |
| TuberculosisInfections and infestations | 1/105 | 0/52 | 0/41 | 0/41 |
| Hepatic Enzyme IncreasedInvestigations | 1/105 | 0/52 | 0/41 | 0/41 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/105 | 0/52 | 0/41 | 0/41 |
| Event | Infliximab + Naproxen | Placebo + Naproxen | Naproxen | No Treatment |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 13/105 | 5/52 | 4/41 | 6/41 |
| BronchitisInfections and infestations | 0/105 | 0/52 | 0/41 | 4/41 |
| Abdominal Pain UpperGastrointestinal disorders | 8/105 | 2/52 | 0/41 | 0/41 |
| DiarrhoeaGastrointestinal disorders | 0/105 | 0/52 | 3/41 | 1/41 |
| RhinitisInfections and infestations | 0/105 | 0/52 | 3/41 | 2/41 |
| HeadacheNervous system disorders | 7/105 | 2/52 | 0/41 | 0/41 |
| DyspepsiaGastrointestinal disorders | 3/105 | 3/52 | 0/41 | 0/41 |
| Age, Continuous(years) | Infliximab + Naproxen | Placebo + Naproxen | Total |
|---|---|---|---|
| Mean | 31.7 ± 8.51 | 30.7 ± 7.34 | 31.4 ± 8.12 |
| Sex: Female, Male(Participants) | Infliximab + Naproxen | Placebo + Naproxen | Total |
|---|---|---|---|
| Female | 33 | 11 | 44 |
| Male | 72 | 40 | 112 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Sep 2009, a primary completion of Apr 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Infliximab · Naproxen